Immupharma (IMM)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

5.17p
   
  • Change Today:
      0.030p
  • 52 Week High: 8.62
  • 52 Week Low: 5.00
  • Currency: UK Pounds
  • Shares Issued: 284.98m
  • Volume: 2,177,712
  • Market Cap: £14.73m
  • RiskGrade: 328

Immupharma Overview

ImmuPharma PLC is a pharmaceutical development company focusing on developing novel medicines in specialist markets with serious unmet need. Lupuzor™ is the company’s most advanced drug in development and is a treatment for lupus, a life threatening autoimmune disease and has now completed dosing Lupus patients in its Phase III pivotal trial. This is only part of our story as our scientists and researchers are developing drugs to make life changing difference to peoples lives worldwide.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn -5491.7% n/a
ROCE n/a  
Latest F'cast
P/E 1.6 n/a
PEG n/a n/a
Pr/Revenue 122.8 n/a
Pr/Book 3.3  
Latest F'cast
Revenue -7.7% -100.0%
PBT n/a n/a
EPS -5.2% -100.0%
DPS n/a n/a

Immupharma Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-17 0.15 (7.00) (4.75)p n/a n/a n/a n/a 0.0%
31-Dec-18 0.08 (7.96) (5.19)p n/a n/a n/a n/a 0.0%
31-Dec-19 0.08 (6.74) (3.99)p n/a n/a n/a n/a 0.0%
31-Dec-20 0.13 (7.25) 3.43p 3.9 n/a n/a n/a 0.0%
31-Dec-21 0.12 (8.94) 3.25p 2.0 n/a -5% n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Immupharma Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-22 n/a n/a n/a n/a n/a -100% n/a 0.0%
31-Dec-23 n/a n/a n/a n/a n/a n/a n/a 0.0%

Copyright © 2022 FactSet Research Systems Inc. All rights reserved.

Immupharma Company Announcements

Result of Broker Option / PDMR Dealings 11-Aug-2022 07:00 RNS
Investor Presentation - Investor Meet Company 04-Aug-2022 07:00 RNS
Second Price Monitoring Extn 03-Aug-2022 16:40 RNS

Immupharma ShareCast News

ImmuPharma making final preparations for Lupuzor... 04-May-2022 ShareCast
ImmuPharma surges on success in latest trial of ... 13-Apr-2022 ShareCast
ImmuPharma updates plan for trials of lupus trea... 07-Feb-2022 ShareCast

Latest Immupharma Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

Immupharma Market Data

Currency UK Pounds
Share Price 5.17p
Change Today 0.030p
% Change 0.58 %
52 Week High 8.62
52 Week Low 5.00
Volume 2,177,712
Shares Issued 284.98m
Market Cap £14.73m
RiskGrade 328

Immupharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
61.43% above the market average61.43% above the market average61.43% above the market average61.43% above the market average61.43% above the market average
82.14% above the sector average82.14% above the sector average82.14% above the sector average82.14% above the sector average82.14% above the sector average
Price Trend
74.26% below the market average74.26% below the market average74.26% below the market average74.26% below the market average74.26% below the market average
21.88% below the sector average21.88% below the sector average21.88% below the sector average21.88% below the sector average21.88% below the sector average
Income Not Available
Growth
22.58% below the market average22.58% below the market average22.58% below the market average22.58% below the market average22.58% below the market average
64.1% below the sector average64.1% below the sector average64.1% below the sector average64.1% below the sector average64.1% below the sector average

Immupharma Dividends

No dividends found

Trades for 11-Aug-2022

Time Volume / Share Price
17:06 200,000 @ 5.17p
16:42 250,000 @ 5.16p
16:13 38 @ 5.14p
16:05 100,000 @ 5.04p
16:01 60,000 @ 5.14p

Immupharma Key Personnel

CEO Timothy Paul McCarthy

Top of Page